SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma receives approval for Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets

27 Sep 2012 Evaluate

Aurobindo Pharma has received tentative approval from the US Food & Drug Administration for Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets, 15mg (base)/500mg and 15mg (base)/850mg (ANDA 200823). The product will be eligible for final approval upon the expiration of 180-day generic drug exclusivity.

Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets, 15mg (base)/500mg and 15mg (base)/850mg are the generic equivalent of Takeda Global Research Development Center Inc’s Actoplus Met Tablets, 15mg (base)/500mg and 15mg (base)/850mg. Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus when treatment with both pioglitazone and metformin is appropriate. The product has a market size of approximately $ 433 Million for the twelve months ending March 2012 according to IMS.

The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad, India

The company now has a total of 159 ANDA approvals (134 Final approvals including 1 from Aurolife Pharma LLC and 25 tentative approvals) from USFDA

Aurobindo Pharma has a product presence in key therapeutic segments like SSPs, cephalosporins, antivirals, CNS, cardio-vascular, gastroenterology, etc. The company is the market leader in semi-synthetic penicillin drugs.

Aurobindo Pharma Share Price

1385.65 -0.45 (-0.03%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×